RU2013105479A - Кристаллическая форма соединения 3-феноксиметилпирролидина - Google Patents

Кристаллическая форма соединения 3-феноксиметилпирролидина Download PDF

Info

Publication number
RU2013105479A
RU2013105479A RU2013105479/04A RU2013105479A RU2013105479A RU 2013105479 A RU2013105479 A RU 2013105479A RU 2013105479/04 A RU2013105479/04 A RU 2013105479/04A RU 2013105479 A RU2013105479 A RU 2013105479A RU 2013105479 A RU2013105479 A RU 2013105479A
Authority
RU
Russia
Prior art keywords
compound according
disorder
peaks
chlorophenoxy
methylpropyl
Prior art date
Application number
RU2013105479/04A
Other languages
English (en)
Russian (ru)
Inventor
Дайсуке Роланд САИТО
Мирослав РАПТА
Original Assignee
Тереванс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44510052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2013105479(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тереванс, Инк. filed Critical Тереванс, Инк.
Publication of RU2013105479A publication Critical patent/RU2013105479A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2013105479/04A 2010-07-09 2011-06-30 Кристаллическая форма соединения 3-феноксиметилпирролидина RU2013105479A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36277310P 2010-07-09 2010-07-09
US61/362,773 2010-07-09
PCT/US2011/042518 WO2012006205A1 (en) 2010-07-09 2011-06-30 Crystalline form of a 3-phenoxymethylpyrrolidine compound

Publications (1)

Publication Number Publication Date
RU2013105479A true RU2013105479A (ru) 2014-08-20

Family

ID=44510052

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013105479/04A RU2013105479A (ru) 2010-07-09 2011-06-30 Кристаллическая форма соединения 3-феноксиметилпирролидина

Country Status (20)

Country Link
US (4) US8163794B2 (https=)
EP (1) EP2590941A1 (https=)
JP (2) JP5823512B2 (https=)
KR (1) KR20130041916A (https=)
CN (1) CN103038211B (https=)
AR (1) AR083512A1 (https=)
AU (1) AU2011276416B2 (https=)
BR (1) BR112013000602A2 (https=)
CA (1) CA2803090A1 (https=)
CL (1) CL2013000085A1 (https=)
CO (1) CO6680604A2 (https=)
IL (1) IL223584A0 (https=)
MX (1) MX2013000334A (https=)
NZ (1) NZ605490A (https=)
PH (1) PH12013500051A1 (https=)
RU (1) RU2013105479A (https=)
SG (1) SG186789A1 (https=)
TW (1) TW201206882A (https=)
WO (1) WO2012006205A1 (https=)
ZA (1) ZA201300154B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
NZ605490A (en) * 2010-07-09 2014-10-31 Theravance Biopharma R & D Ip Llc Crystalline form of a 3-phenoxymethylpyrrolidine compound
US11013340B2 (en) 2018-05-23 2021-05-25 L&P Property Management Company Pocketed spring assembly having dimensionally stabilizing substrate
US12369722B2 (en) 2018-05-23 2025-07-29 L&P Property Management Company Method of disassembling pocketed spring assembly with dimensionally stabilizing substrate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
DE60119047D1 (de) * 2000-08-31 2006-06-01 Pfizer Phenoxyphenylheterozyklen als Serotonin-Wiederaufnahmehemmer
US20070072859A1 (en) * 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
EP2066630A1 (en) * 2006-08-23 2009-06-10 Pfizer Products Incorporated Piperidine derivatives
WO2008153958A2 (en) * 2007-06-08 2008-12-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
WO2010011811A2 (en) * 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
AU2010273645B2 (en) 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
NZ605490A (en) * 2010-07-09 2014-10-31 Theravance Biopharma R & D Ip Llc Crystalline form of a 3-phenoxymethylpyrrolidine compound

Also Published As

Publication number Publication date
CN103038211B (zh) 2015-04-15
AU2011276416B2 (en) 2015-04-02
US20120178790A1 (en) 2012-07-12
US20140018407A1 (en) 2014-01-16
AU2011276416A1 (en) 2013-02-14
US8383669B2 (en) 2013-02-26
ZA201300154B (en) 2013-09-25
US20120010265A1 (en) 2012-01-12
IL223584A0 (en) 2013-03-05
US20150080450A1 (en) 2015-03-19
CO6680604A2 (es) 2013-05-31
SG186789A1 (en) 2013-02-28
MX2013000334A (es) 2013-02-26
CA2803090A1 (en) 2012-01-12
CN103038211A (zh) 2013-04-10
BR112013000602A2 (pt) 2016-07-05
NZ605490A (en) 2014-10-31
PH12013500051A1 (en) 2017-10-25
US8791151B2 (en) 2014-07-29
TW201206882A (en) 2012-02-16
AR083512A1 (es) 2013-03-06
KR20130041916A (ko) 2013-04-25
US8163794B2 (en) 2012-04-24
EP2590941A1 (en) 2013-05-15
WO2012006205A1 (en) 2012-01-12
JP5823512B2 (ja) 2015-11-25
US9120746B2 (en) 2015-09-01
JP2015120752A (ja) 2015-07-02
JP2013532170A (ja) 2013-08-15
CL2013000085A1 (es) 2013-03-15

Similar Documents

Publication Publication Date Title
KR101736218B1 (ko) 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
KR101581289B1 (ko) 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민
RU2011123890A (ru) Кристаллическая форма 4-[2-(2-фторфеноксиметил)фенил]пиперидинового соединения
JP5432526B2 (ja) モノアミン再取り込み阻害剤としてのシクロアルキルアミン
JP6595078B2 (ja) アミノカルボニルカルバメート化合物
RU2015102531A (ru) Офтальмологический состав и способ для облегчения пресбиопии
AU2015210852A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
JP2011527333A5 (https=)
CA2713025A1 (en) Kappa selective opioid receptor antagonist
RU2013105479A (ru) Кристаллическая форма соединения 3-феноксиметилпирролидина
RU2492163C9 (ru) Соединения коричной кислоты (варианты), промежуточные соединения для их получения, фармацевтическая композиция на их основе, способ ингибирования гистоновой деацетилазы, способ лечения диабета, способ лечения опухоли или заболевания, связанного с пролиферацией клеток, способ усиления роста аксонов и способ лечения нейродегенеративных заболеваний и спинной мышечной атрофии
CN1192199A (zh) 2－(4－取代)－苄基氨基－2－甲基－丙酰胺衍生物
JP2011529069A5 (https=)
RU2017139002A (ru) Пироглутамат вортиоксетина
US20230218562A1 (en) Aminocarbonylcarbamate compounds
JPWO2012074069A1 (ja) 新規化合物及びその医薬用途
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида
JP2013532170A5 (https=)
JP2007522147A5 (https=)
CN1630631A (zh) 新的文拉法星盐酸盐多晶型物及其制备方法
CN1163471C (zh) 3-羟基-丙胺衍生的神经元重吸收抑制剂
JP2019535715A5 (https=)
JP2014001142A (ja) シクロアルカン化合物
JP2013516490A5 (https=)
TW202237622A (zh) 雜環化合物的鹽及其晶型、製備方法、治療用途與醫藥組合物

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160512